Institute for International Research

Dear Colleague,

When was the last time you sat in a room with 50 senior level pharmaceutical risk management leaders? Or when was the last time you were privy to the outcomes of a “Meeting of the Minds” risk management working group? Now the first time, 50 of the key industry risk management leaders will convene to discuss their concerns, best practices, and next practices in dealing with managing risk under the microscope of post-approval regulation.

The Exclusive Invite-Only Executive Task Force will convene on May 21, 2008. Moderated by Christopher-Paul Milne, Tufts Center for the Study of Drug Development, this comprehensive day will cover your most pressing issues in an informal discussion format.
I. Developing a Risk Management System
II. Lifecycle Management Approach to Drug Safety
III. Balancing the Benefi t/Risk
IV. Global Risk Minimization

THE MAIN EVENT

On May 22nd and 23rd, 2008, the fi ndings of the Executive Task Force will be presented by a panel from the summit working group during the main conference. Not only will you hear from our Executive Task Force Panel, our main conference will provide insights from our expert speaking faculty to improve your risk management strategies for increased drug value and safety.

• Blue Cross Blue Shield discusses Developing Outcome Research Required for Managed Care Institutes Around Patient Safety and Efficacy
• Novartis on Post-Approval Studies to Assess Product Safety and Identify Potential Risk
• Purdue Pharmaceuticals on calculating the benefi t/risk balance and risk management plans for Oxycontin
• Pfizer on Increasing Pharmaceutical Safety Using Electronic Health Records

Plus! What’s on the Horizon?
Three Featured Sessions that Discuss the Future of Drug Safety and Risk Management in the Pharmaceutical Industry

• The Public Perception of the Pharmaceutical Industry and Drug Safety: How to Engage the Public to be Part of the Solution
  
• Navigating the Regulatory Burden of Global Companies: A Side-by-Side Comparison of the Risk Management Regimes of the FDA, EMEA and MHLW
  
• Increasing Pharmaceutical Safety Using Electronic Health Records

Sincerely,

Jennie Friedlich
Event Director, Pharmaceutical Division
Institute for International Research